Refractory Hematologic Malignancy
Associated Genetic Biomarkers
NCI Definition: A hematologic malignancy that is resistant to treatment. 
There is 1 clinical trial for refractory hematologic malignancy, of which 0 are open and 1 is completed or closed. Of the trial that contains refractory hematologic malignancy as an inclusion criterion, 1 is phase 2 (0 open).
IL3RA is the most frequent gene inclusion criterion for refractory hematologic malignancy clinical trials .
Flotetuzumab is the most common intervention in refractory hematologic malignancy clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.